PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31802616-5	2020	The primary outcome of the study was the mean change in arginine-stimulated insulin secretion rate during the hyperglycemic clamp test from baseline to 16-week therapy RESULTS: At week 16, BMI declined in all groups (-1.2+-0.2 Kg/m2 ; p<0.05).	Arginine Vasopressin	56-64	insulin	Homo sapiens	76-83	
31730979-7	2020	Docking experiment and subsequent molecular dynamics simulation indicated possible sites of interaction for arginine with the B-chain of insulin.	Arginine Vasopressin	108-116	insulin	Homo sapiens	137-144	
32077280-5	2020	In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.	Arginine Vasopressin	140-148	insulin	Homo sapiens	87-94	
31983031-4	2020	RESULTS: At both 4 and 24 weeks post-RYGB the following effects were found: arginine-stimulated insulin secretion was reduced.	Arginine Vasopressin	76-84	insulin	Homo sapiens	96-103	
31652143-1	2020	PURPOSE OF REVIEW: Because arginine is the substrate for nitric oxide synthesis, which is pivotal to vascular homeostasis and linked to the insulin response, it has long been posited that supplemental arginine could benefit cardiometabolic health.	Arginine Vasopressin	27-35	insulin	Homo sapiens	140-147	
31652143-1	2020	PURPOSE OF REVIEW: Because arginine is the substrate for nitric oxide synthesis, which is pivotal to vascular homeostasis and linked to the insulin response, it has long been posited that supplemental arginine could benefit cardiometabolic health.	Arginine Vasopressin	201-209	insulin	Homo sapiens	140-147